Renovis

Renovis is a science-driven, biopharmaceutical company that seeks to discover, develop and commercialize therapeutics for major medical needs in the areas of neurological and inflammatory diseases. Our goal is to create a sustainable pipeline of first- and best-in-class product candidates that will improve the lives of patients as well as provide superior returns to our investors. We are pursuing this goal by investing strategically in our internal drug discovery activities and by applying our expertise to the selection and acquisition of external programs of equal quality and promise. Over time, we expect this blended approach to yield a balanced portfolio of high-potential product candidates that we can commercialize ourselves or with partners. Our integrated capabilities in small molecule drug discovery, including medicinal chemistry, bioinformatics, molecular biology, and pharmacology, enable us to identify and select drug candidates that meet stringent standards for development. This approach has yielded multiple lead candidates in our preclinical programs for pain and inflammation. Our proprietary preclinical programs are focused on identifying antagonists of selected purinergic receptors as novel potential treatments for a broad spectrum of pain and inflammatory conditions. In addition, we have entered into a collaboration with Pfizer Inc. (Pfizer) to discover and develop product candidates targeting the vanilloid receptor, VR1, for the potential treatment of pain and other diseases and disorders, as well as a collaboration with Genentech, Inc. (Genentech) in the areas of nerve growth and anti-angiogenesis. We currently have more than 60 employees based in South San Francisco, California, who are united in their commitment to translating great science into groundbreaking medicines that improve the lives of patients.

Contact Details: Two Corporate Drive South San Francisco CA 94080-7047 United States of America Tel: (650) 266 1400 Fax: (650) 266 1460 Email: WWW: www.renovis.com/

Loading...

Recent Publications by Renovis:
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors. The screening of known medicinal agents against new biological targets has...	24th October, 2009	Renovis, Inc, South San Francisco, CA 94080, USA.	Bioorg Med Chem Lett. 2009 Dec 1;19(23):6793-6. Epub 2009 Sep 30. DOI Direct Link
Identification and characterization of novel TRPV4 modulators. TRPV4, a close relative of the vanilloid receptor TRPV1, is activated by...	10th September, 2009	In Vitro Pharmacology Department, Renovis, Inc., South San Francisco, CA	Biochem Biophys Res Commun. 2009 Nov 20;389(3):490-4. Epub 2009 Sep 6. DOI Direct Link
Technical advances: genome-wide cDNA-AFLP analysis of the Arabidopsis transcriptome. cDNA-AFLP, a technology historically used to identify small numbers of...	17th March, 2004	Ceres,	OMICS. 2003 Summer;7(2):143-59.
Cholinergic and GABAergic pathways in fly motion vision. BACKGROUND: The fly visual system is a highly ordered brain structure with...	17th April, 2003	Friedrich-Miescher-Laboratorium der Max-Planck-Gesellschaft Spemannstr,	BMC Neurosci. 2001;2:1. Epub 2001 Feb 9.

Press Releases on Renovis:
iZumi Bio Appoints Dr. Corey Goodman to Board of Directors and Scientific Advisory Board	11th June, 2009	iZumi Bio, Inc.	SOUTH SAN FRANCISCO, Calif., June 11 /PRNewswire/ -- iZumi Bio, Inc., a biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of
iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development	6th May, 2009	iZumi Bio, Inc.	SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- iZumi Bio, Inc., a biotechnology company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of
iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer	12th February, 2009	iZumi Bio, Inc.	MOUNTAIN VIEW, Calif., Feb. 12 /PRNewswire/ -- iZumi Bio, Inc., announced today the appointment of John P. Walker as Chief Executive Officer and a member of the company's Board of Directors.
Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer	6th August, 2008	Nektar Therapeutics	SAN CARLOS, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Randall Moreadith, M.D., Ph.D., to the position of Senior Vice President

BioNews Results for Renovis:
Evotec to Voluntarily Delist From NASDAQ	Pharmacy Choice:  Nov 10 2009 10:58PM Matching: renovis
Evotec to Voluntarily Delist From NASDAQ	Therapeutics Daily:  Nov 10 2009 11:20AM Matching: renovis
Ex-Pfizer S.F. chief Goodman joins another biotech board	Houston Business Journal:  Oct 12 2009 5:15AM Matching: renovis
Ex-Pfizer S.F. chief Goodman joins another biotech board	Charlotte Business Journal:  Oct 8 2009 6:05AM Matching: renovis
NeuroTherapeutics Pharma names new board member	Therapeutics Daily:  Oct 7 2009 4:21AM Matching: renovis
Promote your company here: BioNewsCast - Press Release Distribution	→View more Renovis news.

Renovis Clinical Trials:
Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

Renovis Patents:
US Patent No.	Title
7576099	Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
6759433	Acetamidobenzamide compounds for neurodegenerative disorders
6835754	Use of aryl nitrone compounds in methods for treating neuropathic pain
6998419	3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
7005546	Acetamidobenzamide compounds for neurodegenerative disorders
→View more Renovis patents.

Renovis (RNVS) Financial information Links from Barchart
RNVS Quote from from Barchart.com
RNVS Chart from from Barchart.com
RNVS Profile from from Barchart.com
RNVS Opinion from from Barchart.com
→View more Renovis finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 406 times since April 2007, the link to the organisation's website has been followed 73 times

Recent Search Terms used to find this page: Renovis TRPV4 | In Vitro Pharmacology Department Renovis Inc. | .

Search for more companies in South San Francisco

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Renovis